Cytokinetics, Incorporated (CYTK)
NASDAQ: CYTK · Real-Time Price · USD
33.16
-0.75 (-2.21%)
Jun 27, 2025, 4:00 PM - Market closed

Cytokinetics Statistics

Total Valuation

Cytokinetics has a market cap or net worth of $3.96 billion. The enterprise value is $3.93 billion.

Market Cap 3.96B
Enterprise Value 3.93B

Important Dates

The next estimated earnings date is Thursday, August 7, 2025, after market close.

Earnings Date Aug 7, 2025
Ex-Dividend Date n/a

Share Statistics

Cytokinetics has 119.43 million shares outstanding. The number of shares has increased by 18.23% in one year.

Current Share Class 119.43M
Shares Outstanding 119.43M
Shares Change (YoY) +18.23%
Shares Change (QoQ) +0.36%
Owned by Insiders (%) 0.46%
Owned by Institutions (%) 115.84%
Float 118.83M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio 200.36
Forward PS 68.72
PB Ratio n/a
P/TBV Ratio n/a
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales 204.62
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 5.99

Current Ratio 5.99
Quick Ratio 5.89
Debt / Equity n/a
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage -6.14

Financial Efficiency

Return on Equity (ROE) n/a
Return on Assets (ROA) -34.12%
Return on Invested Capital (ROIC) -70.51%
Return on Capital Employed (ROCE) -51.22%
Revenue Per Employee $38,590
Profits Per Employee -$1.24M
Employee Count 498
Asset Turnover 0.02
Inventory Turnover n/a

Taxes

Income Tax n/a
Effective Tax Rate n/a

Stock Price Statistics

The stock price has decreased by -35.92% in the last 52 weeks. The beta is 0.59, so Cytokinetics's price volatility has been lower than the market average.

Beta (5Y) 0.59
52-Week Price Change -35.92%
50-Day Moving Average 34.10
200-Day Moving Average 45.08
Relative Strength Index (RSI) 49.91
Average Volume (20 Days) 1,401,119

Short Selling Information

The latest short interest is 14.01 million, so 11.73% of the outstanding shares have been sold short.

Short Interest 14.01M
Short Previous Month 14.50M
Short % of Shares Out 11.73%
Short % of Float 11.79%
Short Ratio (days to cover) 8.37

Income Statement

In the last 12 months, Cytokinetics had revenue of $19.22 million and -$615.26 million in losses. Loss per share was -$5.30.

Revenue 19.22M
Gross Profit -338.46M
Operating Income -565.64M
Pretax Income -545.28M
Net Income -615.26M
EBITDA -556.14M
EBIT -565.64M
Loss Per Share -$5.30
Full Income Statement

Balance Sheet

The company has $938.22 million in cash and $910.46 million in debt, giving a net cash position of $27.76 million or $0.23 per share.

Cash & Cash Equivalents 938.22M
Total Debt 910.46M
Net Cash 27.76M
Net Cash Per Share $0.23
Equity (Book Value) -266.41M
Book Value Per Share -2.23
Working Capital 796.33M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$398.00 million and capital expenditures -$9.57 million, giving a free cash flow of -$407.57 million.

Operating Cash Flow -398.00M
Capital Expenditures -9.57M
Free Cash Flow -407.57M
FCF Per Share -$3.41
Full Cash Flow Statement

Margins

Gross Margin n/a
Operating Margin -2,943.30%
Pretax Margin -3,201.47%
Profit Margin n/a
EBITDA Margin n/a
EBIT Margin n/a
FCF Margin n/a

Dividends & Yields

Cytokinetics does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -18.23%
Shareholder Yield -18.23%
Earnings Yield -15.54%
FCF Yield -10.29%
Dividend Details

Analyst Forecast

The average price target for Cytokinetics is $70.92, which is 113.87% higher than the current price. The consensus rating is "Buy".

Price Target $70.92
Price Target Difference 113.87%
Analyst Consensus Buy
Analyst Count 14
Revenue Growth Forecast (5Y) 140.78%
EPS Growth Forecast (5Y) n/a
Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value n/a
Lynch Upside n/a
Graham Number n/a
Graham Upside n/a

Stock Splits

The last stock split was on June 25, 2013. It was a reverse split with a ratio of 0.1666666:1.

Last Split Date Jun 25, 2013
Split Type Reverse
Split Ratio 0.1666666:1

Scores

Cytokinetics has an Altman Z-Score of -1.46 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score -1.46
Piotroski F-Score 3